In order to compete globally, Europe has to innovate and develop nanomedicines and medical technologies with high value and high technological content, well protected IP, and ensuring both a clinical need and commercial opportunities of all new innovations. Technically, this will be achieved by combining elements of key enabling technologies like nanotechnologies, photonics, robotics, advanced materials and information technologies to get smart medical devices and smart nanomedicines. However, the translation of the preclinical proof of concepts to the market via clinical validation, regulatory approval, and approval for reimbursement by the healthcare systems, requires a more integrated and streamlined ecosystem with less barriers between stakeholders and steps. Following their successful experience in the past 12 years of development in nanomedicine and medical technologies, ETPN and the seven other partners of NOBEL are merging their networks to set up a coherent, robust and unique ecosystem where information flow will improve awareness all along the value chain right up to the market access. It develops interactions, cooperation and implementation of complementary actions at local, regional, national, European and even international levels. The building of this ecosystem is based on two main pillars: a joint vision of the strategy for the future (roadmapping) and a high cohesion and interrelationship among the members of the ecosystem. One of the most significant and impactful outputs of this inclusive efficient ecosystem is the tangible acceleration of the development and industrialization of innovative SMEs in nanomedicine and medical technologies. This will impact the renaissance of EU economy by creating jobs and value in Europe. NOBEL will be unique in building the most efficient network of connections and synergies all along the value chain of Nanomedicine and healthcare technologies in Europe.

ERA4Health Partnership Phase 2 is aimed to integrate new additional activities to the current ERA4Health Partnership. The main ambition of the partnership it is the contribution to the goal of Europe to be at the forefront of science and innovation in Health Research by 2050 and enhancing the biomedical research to provide a better health for citizens, not only in Europe but at international level. To be able to achieve this aim, ERA4Health Phase 2 will pursue the following specific objectives: SO1. Support relevant medical research including clinical fields and intervention areas (prevention, diagnosis, treatment) SO2. Improve the utilisation of existing health technologies in clinical practice SO3. Build capacity, in particular in conducting IICSs at European scale SO4. Implement and advance the practice of RRI across the breadth of the programme This Phase 2 of the Partnership will continue supporting relevant medical research and new knowledge generation in the research priority areas stablished in the ERA4Health long-term Strategic Research and Innovation Agenda (SRIA), with a particular focus devoted to support and fund multi-country Investigator-Initiated Clinical Studies (IICS). The research priority areas included in the SRIA are: nutrition and life-style related diseases, prevention and public health strategies, cardiovascular diseases, nano and advanced technologies for disease prevention, diagnostic and therapy. ERA4Health will fund non-commercial multi-country IICS to enhance this impactful and added value clinical research. The additional activities in ERA4Health Phase 2 will serve to provide support and building capacity in conducting multi-country IICSs and to overcome the identified challenges and obstacles in these type of IICSs.